Viral Haemorrhagic Fevers

Manson's Tropical Diseases: Twenty-Third Edition

Volumn , Issue , 2013, Pages 171-194

  Blumberg, Lucille ^a   Enria, Delia ^b   Bausch, Daniel G ^c  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b Instituto Nacional de Enfermedades Virales Humanas Dr Julio I Maiztegui   (Argentina)

^c TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942847830     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-5101-2.00017-0     Document Type: Chapter

References (90)

1. Bond NG, Moses LM, Peterson AT, et al. Environmental aspects of the viral hemorrhagic fevers. Praeger Handbook of Environmental Health 2012, 133-161. Praeger, Santa Barbara. R. Friis (Ed.).
2. Leffel EK, Reed DS Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror 2004, 2(3):186-191.
3. Reed DS, Lackemeyer MG, Garza NL, et al. Aerosol exposure to Zaire Ebola virus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect 2011, 13(11):930-936.
4. Bausch DG, Peters CJ The viral hemorrhagic fevers. Beyond Anthrax: The Weaponization of Infectious Diseases 2009, Humana Press, New York. L. Lutwick, S.M. Lutwick (Eds.).
5. Bausch DG, Rollin PE Responding to Epidemics of Ebola Hemorrhagic Fever: Progress and Lessons Learned from Recent Outbreaks in Uganda, Gabon and Congo. Emerging Infections 6 2004, ASM Press, Washington, DC. W.M. Scheld, B.E. Murray, J.M. Hughes (Eds.).
6. Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007, 196(Suppl 2):S142-S147.
7. Moraz ML, Kunz S Pathogenesis of arenavirus hemorrhagic fevers. Expert Rev Anti Infect Ther 2011, 9(1):49-59.
8. Mahanty S, Bray M Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004, 4(8):487-498.
9. Aleksandrowicz P, Wolf K, Falzarano D, et al. Viral haemorrhagic fever and vascular alterations. Hamostaseologie 2008, 28(1-2):77-84.
10. Kibadi K, Mupapa K, Kuvula K, et al. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis 1999, 179(Suppl. 1):S13-S14.
11. Ketai L, Alrahji AA, Hart B, et al. Radiologic manifestations of potential bioterrorist agents of infection. AJR Am J Roentgenol 2003, 180(3):565-575.
12. Trombley AR, Wachter L, Garrison J, et al. Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses and New World hantaviruses. American J Trop Med Hyg 2010, 82(5):954-960.
13. Bausch DG, Rollin PE, Demby AH, et al. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test and virus isolation. J Clin Microbiol 2000, 38(7):2670-2677.
14. Zaki SR, Shieh WJ, Greer PW, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999, 179(Suppl. 1):S36-S47.
15. Paweska JT, Sewlall NH, Ksiazek TG, et al. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis 2009, 15(10):1598-1602.
16. Ippolito G, Feldmann H, Lanini S, et al. Viral hemorrhagic fevers: advancing the level of treatment. BMC medicine 2012, 10:31.
17. Roddy P, Colebunders R, Jeffs B, et al. Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options. J Infect Dis 2011, 204(Suppl. 3):S791-S795.
18. Bausch DG, Sprecher AG, Jeffs B, et al. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res 2008, 78(1):150-161.
19. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010, 38(2):367-374.
20. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986, 314(1):20-26.
21. Bausch DG, Hadi CM, Khan SH, et al. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010, 51(12):1435-1441.
22. Hadi CM, Goba A, Khan SH, et al. Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect Dis 2010, 16(12):2009-2011.
23. Gowen BB, Bray M Progress in the experimental therapy of severe arenaviral infections. Future Microbiol 2011, 6(12):1429-1441.
24. Gowen BB, Barnard DL, Smee DF, et al. Interferon alfacon-1 protects hamsters from lethal Pichinde virus infection. Antimicrob Agents Chemother 2005, 49(6):2378-2386.
25. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366(22):2055-2064.
26. CDC and WHO Infection control for viral haemorrhagic fevers in the African health care setting 1998, Centers for Disease Control and Prevention, Atlanta.
27. Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009, 5(7):e1000536.
28. Amman BR, Carroll SA, Reed ZD, et al. Seasonal pulses of Marburg virus circulation in Juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog 2012, 8(10):e1002877.
29. Leroy EM, Epelboin A, Mondonge V, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 2009, 9(6):723-728.
30. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005, 438(7068):575-576.
31. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 2006, 355(9):909-919.
32. Adjemian J, Farnon EC, Tschioko F, et al. Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis 2011, 204(Suppl. 3):S796-S799.
33. Formenty P, Hatz C, Le Guenno B, et al. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 1999, 179(Suppl. 1):S48-S53.
34. Georges AJ, Leroy EM, Renaut AA, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: Epidemiologic and health control issues. J Infect Dis 1999, 179(Suppl. 1):S65-S75.
35. Rouquet P, Froment JM, Bermejo M, et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 2005, 11(2):283-290.
36. Leroy EM, Rouquet P, Formenty P, et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004, 303(5656):387-390.
37. Dowell SF, Mukunu R, Ksiazek TG, et al. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999, 179(Suppl. 1):S87-S91.
38. Ebihara H, Rockx B, Marzi A, et al. Host response dynamics following lethal infection of rhesus macaques with Zaire Ebola virus. J Infect Dis 2011, 204(Suppl. 3):S991-S999.
39. Bray M, Mahanty S Ebola hemorrhagic fever and septic shock. J Infect Dis 2003, 188(11):1613-1617.
40. Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000, 355(9222):2210-2215.
41. Colebunders R, Tshomba A, Van Kerkhove MD, et al. Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness and treatment. J Infect Dis 2007, 196(Suppl. 2):S148-S153.
42. Kortepeter MG, Bausch DG, Bray M Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011, 204(Suppl. 3):S810-S816.
43. Ogawa H, Miyamoto H, Ebihara H, et al. Detection of all known filovirus species by reverse transcription-polymerase chain reaction using a primer set specific for the viral nucleoprotein gene. J Virol Meth 2011, 171(1):310-313.
44. Towner JS, Sealy TK, Ksiazek TG, et al. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 2007, 196(Suppl. 2):S205-S212.
45. de Wit E, Feldmann H, Munster VJ Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies. Genome Med 2011, 3(1):5.
46. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999, 179(Suppl. 1):S18-S23.
47. Olinger GG, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Nat Acad Sci U S A 2012, 109(44):18030-18035.
48. Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012, 4(138):138ra81.
49. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007, 196(Suppl. 2):S390-S399.
50. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003, 362(9400):1953-1958.
51. Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 2003, 41(12):2147-2153.
52. Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011, 204(Suppl. 3):S785-S790.
53. Geisbert TW, Feldmann H Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011, 204(Suppl. 3):S1075-S1081.
54. Falzarano D, Geisbert TW, Feldmann H Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines 2011, 10(1):63-77.
55. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nature Med 2010, 16(9):991-994.
56. Hoenen T, Groseth A, Feldmann H Current Ebola vaccines. Expert Opin Biol Ther 2012, 12(7):859-872.
57. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29(2):304-313.
58. Dery M, Bausch DG A DNA vaccine for the prevention of Ebola virus infection. Curr Opin Mol Ther 2008, 10(3):285-293.
59. Charrel RN, Coutard B, Baronti C, et al. Arenaviruses and hantaviruses: from epidemiology and genomics to antivirals. Antiviral Res 2011, 90(2):102-114.
60. Fichet-Calvet E, Rogers DJ Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis 2009, 3(3):e388.
61. Khan SH, Goba A, Chu M, et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 2008, 78(1):103-115.
62. Briese T, Paweska JT, McMullan LK, et al. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 2009, 5(5):e1000455.
63. Monath TP, Newhouse VF, Kemp GE, et al. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974, 185:263-265.
64. ter Meulen J, Lenz O, Koivogui L, et al. Short communication: Lassa fever in Sierra Leone: UN peacekeepers are at risk. Trop Med Int Health 2001, 6(1):83-84.
65. Mahanty S, Bausch DG, Thomas RL, et al. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J Infect Dis 2001, 183(12):1713-1721.
66. Andersen KG, Shylakhter I, Tabrizi S, et al. Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. Phil Trans R Soc London Series B, Biol Sci 2012, 367(1590):868-877.
67. Asogun DA, Adomeh DI, Ehimuan J, et al. Molecular diagnostics for Lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation. PLoS Negl Trop Dis 2012, 6(9):e1839.
68. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005, 2(6):e183.
69. Charrel RN, Feldmann H, Fulhorst CF, et al. Phylogeny of New World arenaviruses based on the complete coding sequences of the small genomic segment identified an evolutionary lineage produced by intrasegmental recombination. Biochem Biophys Res Commun 2002, 296(5):1118-1124.
70. Enria DA, Briggiler AM, Sanchez Z Treatment of Argentine hemorrhagic fever. Antiviral Res 2008, 78(1):132-139.
71. Ambrosio A, Saavedra M, Mariani M, et al. Argentine hemorrhagic fever vaccines. Hum Vaccin 2011, 7(6):694-700.
72. Macneil A, Nichol ST, Spiropoulou CF Hantavirus pulmonary syndrome. Virus Res 2011, 162(1-2):138-147.
73. Rusnak JM, Byrne WR, Chung KN, et al. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res 2009, 81(1):68-76.
74. Jonsson CB, Hooper J, Mertz G Treatment of hantavirus pulmonary syndrome. Antiviral Res 2008, 78(1):162-169.
75. Schmaljohn C Vaccines for hantaviruses. Vaccine 2009, 27(Suppl 4):D61-D64.
76. Olive MM, Goodman SM, Reynes JM The role of wild mammals in the maintenance of Rift Valley fever virus. J Wildl Dis 2012, 48(2):241-266.
77. Ikegami T, Makino S The pathogenesis of Rift Valley fever. Viruses 2011, 3(5):493-519.
78. Labeaud D Towards a safe, effective vaccine for Rift Valley fever virus. Future Virol 2010, 5(6):675-678.
79. LaBeaud AD, Kazura JW, King CH Advances in Rift Valley fever research: insights for disease prevention. Curr Opin Infect Dis 2010, 23(5):403-408.
80. Ergonul O Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2012, 2(2):215-220.
81. Swanepoel R, Gill DE, Shepherd AJ, et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989, 11(Suppl. 4):S794-S800.
82. Leblebicioglu H, Bodur H, Dokuzoguz B, et al. Case management and supportive treatment for patients with Crimean-Congo hemorrhagic Fever. Vector Borne Zoonotic Dis 2012, 12(9):805-811.
83. Ascioglu S, Leblebicioglu H, Vahaboglu H, et al. Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. J Antimicrob Chemother 2011, 66(6):1215-1222.
84. Mardani M, Rahnavardi M, Sharifi-Mood B Current treatment of Crimean-Congo hemorrhagic fever in children. Expert Rev Anti-infect Ther 2010, 8(8):911-918.
85. Keshtkar-Jahromi M, Kuhn JH, Christova I, et al. Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res 2011, 90(2):85-92.
86. Bond NG, Moses LM, Peterson AT, et al. Environmental aspects of the viral hemorrhagic fevers. Praeger Handbook of Environmental Health 2012, 133-161. Praeger, Santa Barbara. R. Friis (Ed.).
87. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010, 38(2):367-374.
88. CDC and WHO Infection control for viral haemorrhagic fevers in the African health care setting 1998, Centers for Disease Control and Prevention, Atlanta.
89. Towner JS, Sealy TK, Ksiazek TG, et al. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis 2007, 196(Suppl. 2):S205-S212.
90. Macneil A, Nichol ST, Spiropoulou CF Hantavirus pulmonary syndrome. Virus Res 2011, 162(1-2):138-147.